Nuvalent’s $350M offering; FDA lifts partial hold on Zentalis drug

Plus, news about Ascendis Pharma, Korro Bio, Novo Nordisk and Medexus:

Nuvalent offers $350M in shares: The oncology biotech is looking to

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Screening debate: Insufficient evidence to support lung cancer screening for non-smokers

Lung cancer remains the leading cause of cancer-related deaths worldwide. Detecting this disease in its early stages significantly improves survival rates, making low-dose CT screening

August 5, 2024

New TB vaccination strategy could save hundreds of thousands of lives with HIV

Scientists at the University of Pittsburgh School of Medicine have discovered a tuberculosis (TB) vaccination strategy that could prevent the leading cause of death among

October 11, 2023

Engineered E. coli shows promise in cancer immunotherapy

Recent research has shown that certain forms of E. coli bacteria tend to colonize hypoxic areas of the body, including tumors, suggesting they might be

October 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.